Search for


TEXT SIZE

search for



CrossRef (0)
Antibacterial activity of Chamaecyparis obtuse extract and Profile of Antimicrobial Agents Resistance for Metallo-β-lactamase-Producing Pseudomonas aeruginosa
Biomed Sci Letters 2024;30:96-
Published online June 30, 2024;  https://doi.org/10.15616/BSL.2024.30.2.96
© 2024 The Korean Society For Biomedical Laboratory Sciences.

Jonghwa Yum†,*

Department of Clinical Laboratory Science, Dongeui University, Busan 47340, Korea
Correspondence to: Jonghwa Yum. Department of Clinical Laboratory Science, Dongeui University, Busan 47340, Korea.
Tel: +82-51-890-2682, Fax: +82-505-182-6877, e-mail: auxotype@deu.ac.kr

*Professor.
Received May 8, 2024; Revised May 21, 2024; Accepted May 31, 2024.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
In vitro antimicrobial activities of hot water extracts of Chamaecyparis obtuse, for clinical metallo-β-lactamase-Producing Pseudomonas aeruginosa (MBLPA.) was compared to commonly used conventional antimicrobial agents. All MBLPA was susceptible to colistin or amikacin, but also to imipenem 88.6%, meropenem 100%, piperacillin 85.7%, ceftazidime 97.1%, gentamicin 97.1%, and ciprofloxacin 100% were non-susceptible. MIC range to imipenem, meropenem, cefotaxime, ceftazidime, gentamicin, and ciprofloxacin for MBLPA were each 1 - >128 μg/mL, 4 - >128 μg /mL, 4 - >128 μg/mL, 8 - >128 μg/mL, 4 - >128, and 2- >128 μg/mL. MIC range to aztreonam for MBLPA were 1 - 128 μg/mL. MIC90 to imipenem, meropenem, cefotaxime, ceftazidime, gentamicin, and ciprofloxacin for MBLPA were each 32 μg/mL, >128 μg/mL, >128 μg/mL, >128 μg/mL, >128 μg/mL, and 128 μg/mL. MIC90 to colistin and amikacin were each 1 μg/mL and 64 μg/mL. The hot water extracts of C. obtuse leaf had the lowest MIC range (0.25 - >0.5 μL /mL), MIC50 (>0.5 μL/mL), and MIC90 (>0.5 μL/mL) of the clinical MBLPA tested, and it was possible more potent than various conventional antimicrobial agents for MBLPA infection patients. Therefore, it suggested the possibility of using extract components of C. obtuse or their derivatives to treat MBLPA infection patients.
Keywords : Chamaecyparis obtuse, Metallo-β-lactamase-Producing Pseudomonas aeruginosa, Antibacterial activity, Antimicrobial agent